| 228 | 8 | 11 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:研究Survivin、BRAF、Notch1在甲状腺良恶性肿瘤中的差异表达及其与血清指标的关系。方法:将在本院就诊的100例甲状腺癌患者和100例甲状腺腺瘤患者纳入研究,采用Real-time PCR和Western-blot检测肿瘤组织中Survivin、BRAF、Notch1的表达情况,采用酶联免疫吸附法检测血清中血管内皮生长因子(VEGF)含量。结果:甲状腺癌组织中Survivin、BRAF、Notch1的mRNA和蛋白水平均高于甲状腺腺瘤组织,且TNM分期越差,Survivin、BRAF、Notch1的表达量越高;甲状腺癌患者血清中VEGFA、VEGFB、VEGFC的含量均高于甲状腺腺瘤患者;多元线性回归显示,VEGFA、VEGFB、VEGFC均与Survivin、BRAF、Notch1呈正相关。结论:甲状腺癌组织中Survivin、BRAF、Notch1呈高表达,且与血清中血管新生指标VEGF具有良好的相关性。
Abstract：Objective:To study the differential expression of Survivin,BRAF,Notch1 in benign and malignant thyroid tumor and its correlation with serum index.Methods:A total of 100 thyroid cancer patients and 100 thyroid adenoma patients were enrolled,mRNA and protein levels of Survivin,BRAF,Notch1 were assayed by Real-time PCR and Western-blot;VEGF content were assayed by elisa.Results:Survivin,BRAF,Notch1 mRNA and protein levels of thyroid carcinoma tissue were higher than those of thyroid adenoma;as TNM stage became worse,expression of Survivin,BRAF,Notch1 were higher;serum content of VEGFA,VEGFB VEGFC in thyroid carcinoma were higher than those of thyroid adenoma patients;multiple linear regression showed that VEGFA,VEGFB,VEGFC were positively correlated with Survivin,BRAF,Notch1.Conclusion:Survivin,BRAF,Notch1 are highly expressed in thyroid carcinoma tissue and have good correlation with serum angiogenesis index VEGF.
1 华天书,王志强,夏米西努尔·伊力克.甲状腺微小乳头状癌雌激素受体的表达及临床意义.中国全科医学.2012,15(15):1711-1714.
2 Smolle E,Taucher V,Petru E,et al.Targeted treatment of ovarian cancer--the multiple-kinase-inhibitor sorafenib as a potential option[J].Anticancer Res,2014,34(4):1519-1530.
3 Campos M,Ducatelle R,Kooistra HS,et al.Immunohistochemical expression of potential therapeutic targets in canine thyroid carcinoma[J].J Vet Intern Med,2014,28(2):564-570.
4 王海莹,金美善,张馨木,等.甲状腺乳头状微小癌组织中surcincin、galectin-3和TPO蛋白的表达及其临床意义[J].吉林大学学报(医学版),2014,40(1):150-154.
5 田忠成,邵飞飞,党雪菲,等.Surviving在甲状腺癌中的表达及临床意义[J].中国实验诊断杂志,2014,18(3):390-393.
6 杨洁,李晓江,赵留芳,等.抗凋亡基因Survivin在分化型甲状腺癌中的表达及临床意义.昆明医学院学报,2011,32(10):27-31.
7 江晓燊,解乃昌.甲状腺乳头状癌BRAFV600E突变蛋白质的表达及意义[J].广东医学,2013,34(6):931-933.
8 易文君,钟德玝,邹琼艳.BRAF干扰对甲状腺癌SW579细胞系的影响[J].中南大学学报(医学版),2013,38(6):576-581.
9 亓龙,左娣,王辉.REGγ、p53、NOTCH1和BRAF在甲状腺癌中的表达及其临床意义[J].华东师范大学学报(自然科学版),2012,6:89-95.
10 吴泽建,谢楚平,蒋基令,等.甲状腺癌中survivin与VEGF因子的表达及其临床意义[J].中国现代医学杂志,2011,21(10):1158-1160.
11 石光清,曹艳.Survivin蛋白和BRAF基因在甲状腺癌中的表达[J].中国现代医学杂志,2012,22(19):61-66.
12 易文君,钟德玝,邹琼燕.BRAF及其细胞外信号调节激酶1/2信号通路蛋白在甲状腺乳头状癌中的表达及意义[J].中南大学学报(医学版),2012,37(9):889-894.
13 杨晶金,姚军,沈峰清,等.Notch-1信号通路与甲状腺乳头状癌的关系[J].中国细胞生物学学报,2012,34(2):120-126.
14 Mancikova V,Inglada-Pérez L,Curras-Freixes M,et al.VEGF,VEGFR3,and PDGFRB Protein Expression Is Influenced by RAS Mutations in MedullaryThyroid Carcinoma[J].Thyroid,2014,24(8):1251-1255.
基本信息:
DOI：10.13210/j.cnki.jhmu.20140918.012
中图分类号:R736.1
引用信息:
[1]刘卫国.Survivin、BRAF、Notch1在甲状腺良恶性肿瘤中的差异表达及其与血清指标的关系[J].海南医学院学报,2015,21(02):250-252+255.DOI:10.13210/j.cnki.jhmu.20140918.012.
基金信息:
湖北省级继续教育项目(2014-04-01-011)~~
2014-09-18
2014-09-18
2014-09-18